호산구 증가증 치료제 시장 예측(-2032년) : 약제 클래스별, 질환 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Eosinophilia Therapeutics Market is accounted for $454.3 million in 2025 and is expected to reach $724.7 million by 2032 growing at a CAGR of 6.9% during the forecast period. Eosinophilia therapeutics encompass a range of treatments designed to manage elevated eosinophil levels, which can result from allergic conditions, parasitic infections, or specific disorders like hypereosinophilic syndrome (HES) and eosinophilic asthma. Therapies include corticosteroids, immunosuppressants, and targeted biologics such as anti-IL-5, anti-IL-4Ra, and anti-IgE monoclonal antibodies. These therapeutics aim to reduce eosinophilic inflammation, prevent organ damage, and improve patient outcomes by modulating the underlying immune response.

According to the European Medicines Agency (EMA), the estimated prevalence of hypereosinophilic syndrome (HES) is 1.5 per 100,000 people.

Market Dynamics:

Driver:

Increasing prevalence of eosinophilic disorders

The rising incidence of eosinophilic disorders serves as a primary growth driver. This increase stems from enhanced diagnostic capabilities that enable earlier detection of rare eosinophilia-related conditions, coupled with growing environmental factors contributing to allergic and inflammatory diseases. Heightened clinical awareness among healthcare professionals has led to improved recognition of eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic esophagitis. The expanding patient population creates substantial demand for targeted treatments, driving pharmaceutical companies to invest heavily in research and development of specialized therapies to address these complex immunological conditions.

Restraint:

High cost of novel therapies

Monoclonal antibodies and targeted biologics, while highly effective, command premium pricing that limits patient accessibility and healthcare system adoption. The specialized nature of these therapies requires extensive clinical trials and regulatory approval processes, contributing to elevated development costs that are ultimately passed to consumers. Insurance coverage limitations and reimbursement challenges further restrict market penetration, particularly in emerging economies where healthcare budgets are constrained, creating disparities in treatment access across different patient populations.

Opportunity:

Development of next-generation biologics and precision medicine

The advancement of precision medicine approaches and innovative biologics targeting specific pathways like IL-5, IL-4, and IL-13 represents tremendous market potential. Ongoing clinical trials of novel eosinophil-targeting therapeutic agents are expanding treatment options beyond traditional corticosteroids. Moreover, personalized medicine strategies enable tailored treatment protocols based on individual patient profiles, improving therapeutic outcomes while reducing adverse effects. The growing understanding of eosinophilic disease mechanisms facilitates the development of more targeted interventions, creating opportunities for pharmaceutical companies to capture market share through differentiated products that address unmet medical needs.

Threat:

Emergence of biosimilars

As patents for original monoclonal antibodies expire, biosimilar manufacturers can offer cost-effective alternatives that potentially erode the market share of branded products. Furthermore, regulatory agencies are streamlining approval pathways for biosimilars, accelerating their market entry and increasing competitive pressure on innovator companies. This threat intensifies price competition and may compress profit margins, forcing original manufacturers to demonstrate superior clinical value or develop next-generation therapies in an increasingly commoditized therapeutic environment.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the eosinophilia therapeutics market through delayed diagnoses and postponed routine medical consultations. Healthcare systems prioritized pandemic response, leading to reduced screening for eosinophilic disorders and interrupted treatment continuity. However, the crisis accelerated telemedicine adoption and digital health integration, creating new patient engagement channels. Additionally, heightened focus on respiratory conditions during the pandemic increased awareness of eosinophilic asthma, potentially driving future market growth as healthcare services normalize.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is expected to account for the largest market share during the forecast period due to their proven effectiveness in rapidly controlling inflammation and their established role as first-line therapy for various eosinophilic conditions. These medications offer broad applicability across allergic, autoimmune, and idiopathic eosinophilic disorders while providing fast symptom relief and accessibility in outpatient settings. Their cost-effectiveness compared to newer biologics makes them preferred choices among clinicians, particularly in resource-constrained healthcare environments, ensuring their sustained market leadership.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, driven by increasing digital healthcare adoption and patient preference for convenient medication access. Digital platforms offer enhanced patient education resources, medication adherence support, and streamlined prescription management systems that improve treatment outcomes. Moreover, the COVID-19 pandemic accelerated e-commerce adoption in healthcare, establishing online pharmacies as viable alternatives to traditional retail channels. Additionally, these platforms often provide competitive pricing, home delivery services, and specialized support for chronic conditions, making them particularly attractive for eosinophilia patients requiring long-term therapeutic management and regular medication refills.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure and high adoption rates of evidence-based pharmacological therapies for eosinophilic disorders. The region benefits from the strong presence of key biopharmaceutical companies specializing in immunological treatments, robust regulatory frameworks, and comprehensive insurance coverage supporting biologic therapies. Furthermore, heightened clinical awareness among healthcare professionals and superior diagnostic capabilities enable early detection and effective management of eosinophil-associated diseases in the region.

Region with highest CAGR:

During the forecast period, the North America region is expected to hold the largest market share due to expanding healthcare infrastructure and increasing awareness of allergic and immunological disorders across the region. Countries like China, India, and Japan represent high-potential markets due to the growing prevalence of eosinophilic diseases, improved diagnostic capabilities, and rising healthcare expenditure. Additionally, enhanced access to biologics and corticosteroid alternatives, combined with growing physician education on eosinophilic disorders, drives strong market expansion. Moreover, government healthcare policies create favorable conditions, positioning Asia Pacific as the fastest growing region.

Key players in the market

Some of the key players in Eosinophilia Therapeutics Market include Allakos, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cipla Inc., Eli Lilly & Company, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Arena Pharmaceuticals Ltd., Ellodi Pharmaceuticals, and Revolo Biotherapeutics.

Key Developments:

In May 2025, GSK plc announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA's approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations versus placebo in a wide spectrum of COPD patients with an eosinophilic phenotype.

In May 2025, AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from 16 to 21 May 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA) and other chronic inflammatory diseases.

In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

Drug Classes Covered:

• Corticosteroids
• Monoclonal Antibodies (Biologics)
• Immunosuppressants
• Proton Pump Inhibitors (PPIs)
• Other Drug Classes

Disease Types:

• Hypereosinophilic Syndrome (HES)
• Eosinophilic Esophagitis (EoE)
• Eosinophilic Asthma
• Eosinophilic Granulomatosis with Polyangiitis (EGPA)
• Other Eosinophilic Disorders

Route of Administrations:

• Oral
• Parenteral (Injectable)
• Inhalation
• Topical

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct Distribution

End Users Covered:

• Hospitals
• Specialty Clinics
• Homecare Settings
• Other Healthcare Facilities

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Eosinophilia Therapeutics Market, By Drug Class

• 5.1 Introduction
• 5.2 Corticosteroids
• 5.3 Monoclonal Antibodies (Biologics)
  • 5.3.1 Anti-IL-5/IL-5Ra
  • 5.3.2 Anti-IL-4Ra
  • 5.3.3 Anti-IgE
  • 5.3.4 Other Emerging Biologics
• 5.4 Immunosuppressants
  • 5.4.1 Hydroxyurea
  • 5.4.2 Interferon-a
  • 5.4.3 Imatinib
• 5.5 Proton Pump Inhibitors (PPIs)
• 5.6 Other Drug Classes

6 Global Eosinophilia Therapeutics Market, By Disease Type

• 6.1 Introduction
• 6.2 Hypereosinophilic Syndrome (HES)
• 6.3 Eosinophilic Esophagitis (EoE)
• 6.4 Eosinophilic Asthma
• 6.5 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
• 6.6 Other Eosinophilic Disorders

7 Global Eosinophilia Therapeutics Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Parenteral (Injectable)
• 7.4 Inhalation
• 7.5 Topical

8 Global Eosinophilia Therapeutics Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Direct Distribution

9 Global Eosinophilia Therapeutics Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Specialty Clinics
• 9.4 Homecare Settings
• 9.5 Other Healthcare Facilities

10 Global Eosinophilia Therapeutics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Allakos, Inc.
• 12.2 AstraZeneca plc
• 12.3 Bayer AG
• 12.4 Bristol-Myers Squibb
• 12.5 Cipla Inc.
• 12.6 Eli Lilly & Company
• 12.7 Gilead Sciences, Inc.
• 12.8 GlaxoSmithKline plc (GSK)
• 12.9 Hoffmann-La Roche Ltd.
• 12.10 Merck & Co., Inc.
• 12.11 Novartis AG
• 12.12 Pfizer Inc.
• 12.13 Regeneron Pharmaceuticals, Inc.
• 12.14 Sanofi S.A.
• 12.15 Takeda Pharmaceutical Company Ltd.
• 12.16 Arena Pharmaceuticals Ltd.
• 12.17 Ellodi Pharmaceuticals
• 12.18 Revolo Biotherapeutics